TrialEmerging microbes & infections2024

Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.

Jia-Wei Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.